NAMS (NewAmsterdam Pharma Co NV) 5-Year EBITDA Growth Rate: -78.80% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAMS NewAmsterdam Pharma Co NV NAMS
44 GF Score
Price $24.92
GF Value $13.30
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is NewAmsterdam Pharma Co NV 5-Year EBITDA Growth Rate?

NewAmsterdam Pharma Co NV NAMS -1.66% 44 5-Year EBITDA Growth Rate is -78.80% as of Jun. 2026. GuruFocus rates NAMS with a GF Score™ of 44/100 and a GF Value™ of $13.30 (Significantly Overvalued). The stock has 3 warning signs investors should review.

NewAmsterdam Pharma Co NV's EBITDA per Share for the three months ended in Jun. 2026 was $-0.53.

During the past 3 years, the average EBITDA Per Share Growth Rate was -17.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -78.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of NewAmsterdam Pharma Co NV was -17.40% per year. The lowest was -201.80% per year. And the median was -54.40% per year.

NewAmsterdam Pharma Co NV  (NAS:NAMS) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

NewAmsterdam Pharma Co NV 5-Year EBITDA Growth Rate Related Terms

NAMS vs IRON, CLDX, IMNM: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's 5-Year EBITDA Growth Rate falls into.


NAMS
44GF Score
NewAmsterdam Pharma Co NV NAMS
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NewAmsterdam Pharma Co NV 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of -78.80% mean?
NewAmsterdam Pharma Co NV (NAMS) has a 5-Year EBITDA Growth Rate of -78.80% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for NewAmsterdam Pharma Co NV and its competitors.
Is NewAmsterdam Pharma Co NV's 5-Year EBITDA Growth Rate too high?
NewAmsterdam Pharma Co NV's current 5-Year EBITDA Growth Rate is -78.80%. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's 5-Year EBITDA Growth Rate compare to IRON and CLDX?
NewAmsterdam Pharma Co NV's 5-Year EBITDA Growth Rate of -78.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for NewAmsterdam Pharma Co NV and its competitors. NewAmsterdam Pharma Co NV's current 5-Year EBITDA Growth Rate is -78.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.30, compared to a current price of $24.92 — trading 87.4% above its estimated fair value. The current 5-Year EBITDA Growth Rate is -78.80%. NewAmsterdam Pharma Co NV's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current 5-Year EBITDA Growth Rate is -78.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?

Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued. The current stock price of $24.92 is trading 87.4% above its estimated GF Value™ of $13.30. GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.

Key valuation signals for NAMS:

  • 5-Year EBITDA Growth Rate: -78.80%
  • GF Value™: $13.30 vs. price of $24.92 (87.4% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NewAmsterdam Pharma Co NV Business Description

Other Exchanges KH6:Germany
Address Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
44GF Score

Get the complete analysis for NAMS

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.92
Price
$13.30
GF Value